舒利迭、爱全乐联合吸入治疗COPD的疗效观察  

Effect of inhaled salmeterol xinafoato and fluticasone propionate ipratropium in the treatment of COPD

作　　者：付翔[1] 

机构地区：[1]郴州市第三人民医院呼吸内科,湖南郴州423000

出　　处：《临床肺科杂志》2010年第7期926-927,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨单药与联合吸入支气管舒张剂对COPD的疗效。方法 51例患者随机分成A组(17例),B组(17例),C组(17例),分别测定基础肺功能。A组吸入爱全乐,B组吸入舒利迭,C组吸入爱全乐加舒利迭。于第1,8,15天测吸药后1h的功能参数FEV1,FVC。结果用药后各组FEV1,FVC较基础值有明显差异(P<0.01),C组△FEV1,△FVC明显高于A,B组,(P<0.01)。结论联合应用吸入支气管舒张剂对COPD患者由明显的气道扩张作用。Objective To evaluate the effects of inhaled bronchodiletors in the treatment of COPD.Methods Fifty-one patients with COPD were divided into three groups at random：A,B and C.The baseline pulmonary function was measured separately.Group A were inhaled ipratropium.Group B were inhaled Salmetrol Xinafoato and fluticasome propionate.Group C were inhaled ipratropium Salmeterol Xinafoato and fluticasone propionate.The subjects were tested on FEV1 and FVC on 1st,1th,8th and 15th days of the treatment.Results FEV1 and FVC increased significantly in the three groups after inhalation （P〈0.01）,there was significant improvement of the mean peak percent increase in FEV1 and FVC over baseline in the group C as compared with the group C （P〈0.01）.Conclusion The inhalation of compound preparation has rapid and long bronchodilation on COPD.

关 键 词：慢性阻塞性肺病 支气管扩张剂肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]